Artiva's AlloNK Shows 71% ACR50 Response in Refractory RA, FDA Aligns on Phase 3 Trial
Event summary
- Artiva's AlloNK® demonstrated a 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with six months of follow-up in a Phase 2a basket trial.
- FDA aligned on a single Phase 3 registrational trial design for AlloNK in refractory RA, expected to enroll approximately 150 patients.
- More than 70 autoimmune patients treated with AlloNK across over 40 active clinical sites, mostly in community settings.
- Phase 3 trial initiation planned for H2 2026, with primary efficacy data expected in H2 2028 and potential BLA submission in 2029.
The big picture
Artiva's positive initial clinical data for AlloNK in refractory RA positions the company to address a significant unmet need in the autoimmune disease space. The FDA's alignment on a Phase 3 trial design accelerates the path to potential approval, while the outpatient administration profile could enhance accessibility and adoption. The broader autoimmune dataset, including responses in Sjögren disease and systemic sclerosis, suggests potential for AlloNK across multiple B-cell driven autoimmune indications.
What we're watching
- Clinical Efficacy
- Whether AlloNK can sustain the observed 71% ACR50 response rate in the larger Phase 3 trial.
- Regulatory Pathway
- The pace at which the FDA will review and approve the Phase 3 trial design and subsequent BLA submission.
- Market Potential
- How AlloNK's outpatient administration profile will impact adoption in community rheumatology settings.
Related topics